Optimal Meropenem Concentrations To Treat Multidrug-Resistant Pseudomonas aeruginosa Septic Shock

ABSTRACT A patient with septic shock due to extensively drug resistant (XDR) Pseudomonas aeruginosa was cured by optimizing the meropenem (MEM) regimen to obtain at least 40% of the time between two administrations in which drug levels were four times higher than the MIC of the pathogen. As the standard drug dose did not achieve these optimal concentrations, the MEM regimen was progressively increased up to 12 g/day (3 g every 6 h in a 3-h extended infusion), which eventually resulted in sepsis resolution. High MEM dosage may represent a valuable therapeutic option for infection due to multidrug-resistant (MDR) strains, and drug monitoring would allow rapid regimen adjustment in clinical practice.

[1]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  A. Pollard.  Infectious disease: Childhood meningitis may be preventable if we can afford it , 2011, Nature Reviews Neurology.

[3]  J. Roberts,et al.  Implications of augmented renal clearance in critically ill patients , 2011, Nature Reviews Nephrology.

[4]  J. Vincent,et al.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy , 2011, Critical care.

[5]  H. Giamarellou.  Multidrug-resistant Gram-negative bacteria: how to treat and for how long. , 2010, International journal of antimicrobial agents.

[6]  Frédérique Jacobs,et al.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock , 2010, Critical care.

[7]  M. Berger,et al.  Prospective monitoring of cefepime in intensive care unit adult patients , 2011 .

[8]  D. Nicolau,et al.  Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – A review of 3 cases , 2010 .

[9]  Darrell R. Abernethy,et al.  Effect of Obesity on the Pharmacokinetics of Drugs in Humans , 2010, Clinical pharmacokinetics.

[10]  D. Paterson,et al.  A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics* , 2009, Critical care medicine.

[11]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[12]  Jerome J. Schentag,et al.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. , 2008, International journal of antimicrobial agents.

[13]  S. Choi,et al.  Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic Use , 2007, Antimicrobial Agents and Chemotherapy.

[14]  J. L. Iribarren,et al.  Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. , 2007, Clinical therapeutics.

[15]  M. Falagas,et al.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? , 2007, International journal of antimicrobial agents.

[16]  D. Nicolau,et al.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. , 2007, Diagnostic microbiology and infectious disease.

[17]  G. Drusano,et al.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Sriwiriyajan,et al.  Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection , 2005, Antimicrobial Agents and Chemotherapy.

[19]  W. Craig,et al.  In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations , 1998, Antimicrobial Agents and Chemotherapy.

[20]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.